#### **BORTEZOMIB EUGIA**

bortezomib

### **Consumer Medicine Information**

This leaflet provides important information about using Bortezomib Eugia. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using Bortezomib Eugia.

Where to find information in this leaflet:

- 1. Why am I using Bortezomib Eugia?
- 2. What should I know before I use Bortezomib Eugia?
- 3. What if I am taking other medicines?
- 4. How do I use Bortezomib Eugia?
- 5. What should I know while using Bortezomib Eugia?
- 6. Are there any side effects?
- 7. Product details

## 1. Why am I using Bortezomib Eugia?

Bortezomib Eugia contains the active ingredient bortezomib. Bortezomib belongs to a group of medicines called antineoplastic or cytotoxic medicines. You may also hear of these being called chemotherapy medicines. These medicines are used to kill cancer cells.

Bortezomib Eugia is used to treat adults with multiple myeloma (cancer of the bone marrow). It is prescribed for patients who have not been previously treated for multiple myeloma. It is also prescribed for patients who have received one or more prior treatments and whose cancer is still progressing.

Bortezomib Eugia is also used for the treatment of mantle cell lymphoma (a type of cancer affecting the lymph nodes) in adults in combination with the medicines rituximab, cyclophosphamide, doxorubicin and prednisone, for patients whose disease has not been previously treated.

# 2. What should I know before I use Bortezomib Eugia?

## Warnings

### Do not use Bortezomib Eugia if:

- you are allergic to bortezomib, boron or any of the ingredients listed at the end of this leaflet
- always check the ingredients to make sure you can use this medicine

## Check with your doctor if you have or have had:

- a blood disorder with a low level of red or white blood cells or platelets. This disorder may become worse during treatment with Bortezomib Eugia.
- diarrhoea or vomiting as this may become worse during treatment with Bortezomib Eugia.